Tamoxifen aziridine labeling of the estrogen receptor - potential utility in detecting biologically aggressive breast tumors

Breast Cancer Research and Treatment

Volumn 40, Issue 3, 1996, Pages 231-241

  Trivedi, Sunil ^a,b   Piccart, Martine ^a   Muquardt, Carl ^a   Gilot, Nathalie ^a   Hadiy, Samira ^a   Patel, Devendra ^b   Leclercq, Guy ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b GUJARAT CANCER AND RESEARCH INSTITUTE   (India)

Author keywords

Aberrant estrogen receptor; Breast cancer; Hormone dependence; Tamoxifen aziridine

Indexed keywords

ESTROGEN RECEPTOR; MONOCLONAL ANTIBODY; TAMOXIFEN AZIRIDINE; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER SURVIVAL; COMPARATIVE STUDY; DRUG LABELING; FEMALE; FLUOROGRAPHY; HORMONAL REGULATION; HORMONAL THERAPY; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RELAPSE;

EID: 0029791308     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01806811     Document Type: Article

References (37)

1. McGuire WL: Hormone receptors: Their role in predicting prognosis and response to endocrine therapy. Semin Oncol 5: 428-433, 1978
2. Green GL, Nolan C, Engler JP, Jensen EV: Monoclonal antibodies to human estrogen receptor. Proc Natl Acad Sci USA 77: 5115-5110, 1980
3. Kumar V, Green S, Stack G, Berry M, Jin JR, Chambon P: Functional domains of the human estrogen receptor. Cell 51: 941-451, 1987
4. Fuqua SAW, Fitzgerald SD, Allred DC, Elledge RM, Nawaz Z, Mc Donnell DP, O'Malley BW, Green GL, McGuire WL: Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res 52: 483-486, 1992
5. Castles C, Fuqua SAW, Klotz DM, Hill SM: Expression of a constitutively active estrogen receptor variant in the estrogen receptor negative BT-20 human breast cancer cell line. Cancer Res 53: 5934-5939, 1993
6. Pfeffer U, Fecarotta E, Castagnetta L, Vidali G: Estrogen receptor variant messager RNA lacking exon 4 in estrogen-responsive human breast cancer cell lines. Cancer Res 53: 741-743, 1993
7. McGuire WL, Chamness GC, Fuqua SAW: Estrogen receptor variants in clinical breast cancer. Mol Endocrinol 5:1571-1577, 1991
8. Garcia T, Lehrer S, Bloomer WD, Schachter B: A variant estrogen receptor messenger ribonucleic acid is associated with reduced levels of estrogen binding in human mammary tissues. Mol Endocrinol 2: 785-791, 1988
9. Dotzlaw H, Alkhalaf M, Murphy LC: Characterization of estrogen receptor variant mRNAs from human breast cancer. Mol Endocrinol 6: 773-785, 1992
10. Murphy LC, Hilsenbeck SG, Dotzlaw H, Fuqua SAW: Relationship of clone 4 estrogen receptor variant messenger RNA expression to some known prognostic variables in human breast cancer. Clinical Can Res 1: 155-159, 1995
11. Piccart MJ, Muquardt C, Bosman C, Pirotte P, Veenstra S, Grillo F, Leclercq G: Comparison of tritiated estradiol and lamoxifen aziridine for measurement of estrogen receptors in human breast cancer cytosols. J Natl Cancer Inst 83:1553-1559, 1991
12. Giambiagi N, Pasqualini JR: Transformation of the estrogen receptor detected by two monoclonal antibodies. J Steroid Biochem 34: 297-300, 1989
13. European Organization for Research and Treatment of Cancer: Breast Cancer Co-operative Group. Revision of the standards for the assessment of hormone receptors in human breast cancer: report of the second E.O.R.T.C. Workshop, held March 16-17 in The Netherlands Cancer Institute. Eur J Cancer 16: 1513-1515, 1980
14. Horigome T, Ogata F, Golding TS, Korach KS: Estradiol stimulated proteolytic cleavage of the estrogen receptor in mouse uterus. Endocrinology 123: 2540-2548, 1988
15. Maaroufi Y, Trivedi S, Leclercq G: Major molecular weight heterogeneity of estrogen receptor from breast cancer is not related to neoplasia. Cancer Biochem Biophys 15: 67-78, 1995
16. Maaroufi Y, Leclercq G: Importance of A/B and C domains of the estrogen receptor for its adsorption to hydroxylapatite. J Steroid Biochem Mol Biol 48: 155-163, 1994
17. Salomonsson M, Häggblad J, O'Malley BW, Sitbon GM: The human estrogen receptor hormone binding domain dimerizes independently of ligand activator. J Steroid Biochem Mol Biol 48: 447-452, 1994
18. McCague R, Potter KA: Synthesis of 4-stannylated tamoxifen analogues: useful precursors to radiolabeled iodoxifene and aziridinyl 4-iodotamoxifen. J Lab Comp Radiopharm 34: 297-302, 1994
19. Rees JC, Wooge CH, Katzenellenbogen BS: Identification of two cysteines closely positioned in the ligand binding pocket of the human estrogen receptor: Roles in ligand binding and transcriptional activation. Mol Endocrinol 6: 2160-2166, 1992
20. Toulas C, Barraille P, Delassus F, Bayard F, Prats H, Faye JC: Differential initiation of translation of a single estrogen receptor mRNA could explain some estradiol resistance cases. Horm Res 38: 73-77, 1992
21. Sluyser M: Role of estrogen receptor variants in the development of hormone resistance in breast cancer. Clin Biochem 25: 407-414, 1992
22. Pakdel F, Katzenellenbogen BS: Human estrogen receptor mutants with altered estrogen and antiestrogen ligand discrimination. J Biol Chem 267: 3429-3437, 1992
23. Danielian PS, White R, Hoare SA, Fawell SE, Parker MG: Identification of residues in the estrogen receptor that confer differential sensitivity to estrogen and hydroxytamoxifen. Mol Endocrinol 7: 232-240, 1993
24. Borgna JL, Scali J: Differential inhibition of estrogen and antiestrogen binding to the estrogen receptor by diethylpyrocarbonate. J Steroid Biochem 31: 427-436, 1988
25. Borgna JL, Scali J: Differential interactions of estrogens and antiestrogens at the 17β-hydroxy or counterpart function with the estrogen receptor. Eur J Biochem 199: 575-585, 1991
26. Koeherst SKA, Jacobs HM, Thijssen JHH, Bhinkenstein MA: Detection of an oestrogen receptor-like protein in human meningiomas by band shift assay using a synthetic oestrogen responsive element (ERE). Br J Cancer 68: 290-294, 1993
27. Sluyser M: Mutations in the estrogen receptor gene. Hum Mutations 6: 97-103, 1995
28. Messeri G, Tozzi P, Quercioli M, Cataliotti L, Cardona G: Alkaline phosphatases and steroid receptors in human breast cancer. J Steroid Biochem Mol Biol 37: 269-271, 1990
29. Auricchio F: Phosphorylation of steroid receptors: General review. J Steroid Biochem 32: 613-622, 1989
30. McNaught RW, Dayani N, Smith RG: Receptor interconversion model of hormone action. I. Purification of a factor involved in conferring estradiol binding to the estrogen receptor. Biochem 29: 2685-2690, 1990
31. Migliaccio A, Pagano M, De Goeij CCJ, Di Domenico M, Castoria G, Sluyser M, Auricchio F: Phosphorylation and estradiol binding of estrogen receptor in hormone-dependent and hormone-independent GR mouse mammary tumors. Int J Cancer 51: 733-739, 1992
32. Graham ML, Krett NL, Miller LA, Leslie KK, Gordon DF, Wood WM, Wei LL, Horwitz KB: T47Dco cells, genetically unstable and containing estrogen receptor mutations, are a model for the progression of breast cancers to hormone resistance. Cancer Res 50: 6208-6217, 1990
33. Fuqua SAW, Falette NF, McGuire WL: Sensitive detection of estrogen receptor RNA by polymerase chain reaction assay. J Natl Cancer Inst 82: 858-861, 1990
34. Murphy LC: Estrogen receptor variants in human breast cancer. Mol Cell Endocrinol 74: C83-C86, 1990
35. Castles CG, Klotz DM, Fuqua SAW, Hill SM: Coexpression of wild-type and variant oestrogen receptor mRNAs in a panel of human breast cancer cell lines. Br J Cancer 71:974-980, 1995
36. Foster BD, Cavener DR, Parl FF: Binding analysis of the estrogen receptor to its specific DNA target site in human breast cancer. Cancer Res 51: 3405-3410, 1991
37. Scott GK, Kushner P, Vigne J, Benz CC: Truncated forms of DNA-binding estrogen receptors in human breast cancer. J Clin Invest 88: 700-706, 1991